{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T15:47:28Z","timestamp":1792165648096,"version":"4.4.0"},"reference-count":8,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Cell"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.ccell.2026.08.003","type":"journal-article","created":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T15:02:07Z","timestamp":1792162927000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["One structural class, one treatment? Firmonertinib in PACC-mutant NSCLC"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3236-0321","authenticated-orcid":false,"given":"Derek De-Rui","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5586-5138","authenticated-orcid":false,"given":"James Chih-Hsin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ccell.2026.08.003_bib1","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/S1470-2045(15)00026-1","article-title":"Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6","volume":"16","author":"Yang","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ccell.2026.08.003_bib2","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1038\/s41586-021-03898-1","article-title":"Structure-based classification predicts drug response in EGFR-mutant NSCLC","volume":"597","author":"Robichaux","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.ccell.2026.08.003_bib3","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1200\/JCO-24-02007","article-title":"Pragmatic Randomized Study of Afatinib Versus Chemotherapy for Patients With Non-Small Cell Lung Cancer With Uncommon Epidermal Growth Factor Receptor Mutations: ACHILLES\/TORG1834","volume":"43","author":"Miura","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ccell.2026.08.003_bib4","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1001\/jamaoncol.2023.5013","article-title":"First-Line Osimertinib for Previously Untreated Patients With NSCLC and Uncommon EGFR Mutations: The UNICORN Phase 2 Nonrandomized Clinical Trial","volume":"10","author":"Okuma","year":"2024","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.ccell.2026.08.003_bib5","first-page":"\u25fc\u25fc\u25fc","article-title":"Firmonertinib in advanced non-small cell lung cancer with epidermal growth factor receptor P-loop and \u03b1C-helix compressing mutations","volume":"44","author":"Le","year":"2026","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ccell.2026.08.003_bib8","doi-asserted-by":"crossref","first-page":"S2048","DOI":"10.1016\/j.annonc.2025.10.683","article-title":"LBA15 Enozertinib (ORIC-114), a highly selective, brain penetrant EGFR and HER2 inhibitor, in previously treated NSCLC with EGFR atypical mutations: Randomized dose optimization and CNS activity","volume":"36","author":"Hong","year":"2025","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ccell.2026.08.003_bib9","article-title":"44P Sunvozertinib showed profound antitumor activities as first-line treatment in advanced NSCLC patients harboring P-loop and alpha C-helix compressing (PACC) or other uncommon mutations","volume":"11","author":"Wang","year":"2026","journal-title":"ESMO Open"},{"key":"10.1016\/j.ccell.2026.08.003_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtho.2025.09.160","article-title":"MA08.04 Phase 2 Interim Results of Zipalertinib in Patients With NSCLC Harboring Uncommon Non-Exon 20 Insertion EGFR Mutations","volume":"20","author":"Udagawa","year":"2025","journal-title":"J. Thorac. Oncol."}],"container-title":["Cancer Cell"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1535610826003594?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1535610826003594?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T15:02:08Z","timestamp":1792162928000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1535610826003594"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":8,"alternative-id":["S1535610826003594"],"URL":"https:\/\/doi.org\/10.1016\/j.ccell.2026.08.003","relation":{},"ISSN":["1535-6108"],"issn-type":[{"value":"1535-6108","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"One structural class, one treatment? Firmonertinib in PACC-mutant NSCLC","name":"articletitle","label":"Article Title"},{"value":"Cancer Cell","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ccell.2026.08.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.ccell.2026.09.011","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}